A. Koch

CERTAIN ASPECTS OF DRUG BINDING TO NONPLASMA PROTEINS AS ILLUSTRATED BY STUDIES WITH CYCLIZINE, CHLORCYCLIZINE, AND POLYMYXIN B

R. Kuntzman, I. Tsai, J. Burchall, 1973, Annals of the New York Academy of Sciences.

The humoral immune response to recombinant nucleocapsid antigen of canine distemper virus in dogs vaccinated with attenuated distemper virus or DNA encoding the nucleocapsid of wild-type virus.

A. Zurbriggen, P. Cherpillod, R. Wittek, 2001, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

S. Dübel, G. Roth, K. Eschke, 2021, Cell Reports.

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD Mutations

S. Dübel, G. Roth, Thomas Klünemann, 2020, SSRN Electronic Journal.

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

S. Dübel, G. Roth, K. Eschke, 2020, bioRxiv.

The distribution and binding of tritiated polymyxin B in the mouse.

R. Kuntzman, J. Burchall, M. Jacobson, 1972, The Journal of pharmacology and experimental therapeutics.